Loading...
OTCM
AURX
Market cap108mUSD
Dec 05, Last price  
2.26USD
1D
0.00%
1Q
26.97%
IPO
13.00%
Name

Nuo Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:AURX chart
P/E
P/S
79.59
EPS
Div Yield, %
Shrs. gr., 5y
13.87%
Rev. gr., 5y
56.34%
Revenues
1m
+124.34%
1,514,4251,948,1551,943,2782,090,7372,066,1843,911,0337,247,39910,564,22011,571,4387,761,93411,510,9772,204,666721,0451,370,594146,17700112,250608,5251,365,173
Net income
-2m
L-26.73%
-6,503,485-2,262,956-5,037,869-7,660,749-3,438,584-6,816,751-3,510,515-19,798,058-20,248,360-18,883,272-52,808,10822,478,307-14,978,711-1,541,827-1,416,353-139,260-90,670-3,025,298-3,171,436-2,323,705
CFO
-2m
L-29.55%
-4,152,260-1,661,170-2,141,094-2,473,021-3,234,098-3,535,367-4,239,489-11,392,819-11,400,996-17,423,270-14,394,714-10,926,437-4,903,954-874,388-4,168-9,847-13,002-3,706,126-3,167,782-2,231,622

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nuo Therapeutics, Inc., a regenerative therapies company, develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing primarily in the United States. Its technology separates autologous blood to produce a platelet based therapy for the chronic wound care market. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was founded in 1998 and is based in Houston, Texas.
IPO date
Jan 19, 2017
Employees
10
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT